Back to Stocks

APYX

Apyx Medical Corp
7 filings tracked
healthcaremedical devicesSMALL ($300M-2B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Apyx Medical is demonstrating a powerful commercial inflection point, reporting a 32.4% year-over-year revenue increase to $12.5 million for the first quarter of 2026.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the headline growth, Apyx Medical faces a precarious financial situation characterized by high-cost debt and persistent cash burn.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every APYX filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing reveals a company in a high-stakes race between commercial scaling and financial exhaustion. On one hand, the top-line momentum is undeniable, with a 32.4% revenue jump and an expanding gross margin profile that suggests the product-market fit for AYON and Renuvion is strong. The ability to leverage the 'GLP-1 ripple effect' provides a compelling long-term growth narrative that could justify the current volatility. However, the underlying capital structure remains the primary headwind. The combination of a high-interest debt load and the pressure of revenue-based covenants transforms the investment into a race against time. Investors must weigh the genuine commercial traction against the risk of a liquidity event if the company cannot transition to cash-flow positivity before its debt obligations or covenant requirements trigger a crisis. The upcoming Q2 FDA decision for AYON will likely serve as the definitive signal for the company's short-term viability.

Selected Quarter

Core Takeaway

Apyx is successfully scaling its Surgical Aesthetics segment, but its financial survival depends on hitting specific revenue targets to satisfy debt covenants.

Investor Lens

The trade-off is between impressive top-line growth and a fragile balance sheet that leaves little room for regulatory or commercial errors.

Watch Next

FDA clearance for AYON power liposuction expansion expected in Q2 2026.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.10Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bearishMay 7

Company continues to report net losses of $2.1 million despite revenue growth.

earnings miss
40%
bullishMay 7

Gross margin increased to 63.5% from 60.1% YoY due to improved product mix.

margin expansion
70%
neutralMay 7

Amended credit agreement with Perceptive to lower revenue targets and add expense caps.

debt restructure
50%
bearishMay 7

Company continues to report net losses of $2.1 million despite revenue growth.

earnings miss
40%
bullishMay 7

Gross margin increased to 63.5% from 60.1% YoY due to improved product mix.

margin expansion
70%
neutralMay 7

Amended credit agreement with Perceptive to lower revenue targets and add expense caps.

debt restructure
50%
bearishMay 7

Company continues to report net losses of $2.1 million despite revenue growth.

earnings miss
40%
bullishMay 7

Gross margin increased to 63.5% from 60.1% YoY due to improved product mix.

margin expansion
70%
neutralMay 7

Amended credit agreement with Perceptive to lower revenue targets and add expense caps.

debt restructure
50%
bearishMay 7

Company continues to report net losses of $2.1 million despite revenue growth.

earnings miss
40%
bullishMay 7

Gross margin increased to 63.5% from 60.1% YoY due to improved product mix.

margin expansion
70%
neutralMay 7

Amended credit agreement with Perceptive to lower revenue targets and add expense caps.

debt restructure
50%
bearishMay 7

Company continues to report net losses of $2.1 million despite revenue growth.

earnings miss
40%
bullishMay 7

Gross margin increased to 63.5% from 60.1% YoY due to improved product mix.

margin expansion
70%
neutralMay 7

Amended credit agreement with Perceptive to lower revenue targets and add expense caps.

debt restructure
50%
bearishMay 7

Company continues to report net losses of $2.1 million despite revenue growth.

earnings miss
40%
bullishMay 7

Gross margin increased to 63.5% from 60.1% YoY due to improved product mix.

margin expansion
70%
neutralMay 7

Amended credit agreement with Perceptive to lower revenue targets and add expense caps.

debt restructure
50%
bearishMay 7

Company continues to report net losses of $2.1 million despite revenue growth.

earnings miss
40%
bullishMay 7

Gross margin increased to 63.5% from 60.1% YoY due to improved product mix.

margin expansion
70%
neutralMay 7

Amended credit agreement with Perceptive to lower revenue targets and add expense caps.

debt restructure
50%

Filing History

10-QMay 7, 2026
Expand Sequence

The Q1 2026 filing reveals a company in a high-stakes race between commercial scaling and financial exhaustion. On one hand, the top-line momentum is undeniable, with a 32.4% revenue jump and an expanding gross margin profile that suggests the product-market fit for AYON and Renuvion is strong. The ability to leverage the 'GLP-1 ripple effect' provides a compelling long-term growth narrative that could justify the current volatility. However, the underlying capital structure remains the primary headwind. The combination of a high-interest debt load and the pressure of revenue-based covenants transforms the investment into a race against time. Investors must weigh the genuine commercial traction against the risk of a liquidity event if the company cannot transition to cash-flow positivity before its debt obligations or covenant requirements trigger a crisis. The upcoming Q2 FDA decision for AYON will likely serve as the definitive signal for the company's short-term viability.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.